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doi:10.1016/j.jmii.2010.04.004A case of nonpigmented Chromobacterium violaceum bacteremic cellulitis after fish bite in
Taiwan is reported. The patient was successfully treated with ciprofloxacin and doxycycline
for an extended period. Chromobacterium violaceum should be listed in the differential diag-
nosis of patients with nonspecific cellulitis associated with marked leukocytosis and rapid
progression to septicemia either with or without a distinct history of exposure to water or soil.
A combination of prompt diagnosis, optimal antimicrobial therapy, and adequate therapeutic
duration for C violaceum infection is the key for successful therapy.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Chromobacterium violaceum is known to be a natural
inhabitant with ubiquitous distribution in soil and water of
tropical and subtropical areas.1 Human infections are rare
and sporadic in the world. Nevertheless, its excessive
virulence usually causes life-threatening sepsis once con-
tracted.1e3 Infection caused by the nonpigmented strain of
C violaceum is rare, but it does cause the same serious
morbidity as the pigmented strain does.2 Clinically, it is
impossible to differentiate between infections caused byInfectious Diseases, Depart-
Tzu Chi General Hospital,
aipei, Taiwan.
om.tw.
an Society of Microbiology. PublC violaceum and other possible microorganisms by patient’s
initial presentation. It is, therefore, important to alert the
clinician to be aware of this pathogen and its clinical
spectrum of infection. Here, a case with nonpigmented C
violaceum bacteremic cellulitis after fish bite in Taiwan is
reported. He was successfully treated with ciprofloxacin
and doxycycline for an extended period. A combination of
prompt diagnosis, optimal antimicrobial therapy, and
adequate therapeutic duration for C violaceum infection is
the key for successful therapy.Case report
In August 2009, a 64-year-old diabetic married man was
brought to the emergency room of Buddhist Tzu Chi General
Hospital, Taipei Branch, located in Taipei County, with a 3-ished by Elsevier Taiwan LLC. All rights reserved.
402 C.-H. Yangday history of intractable pain over right lower extremity,
severe headache, and persistent high fever. Three days
before this entry, he had experienced a fish bite during
fishing along a river. This fish (Tilapia) slipped and fell on his
right foot when it was just removed from the hook and then it
bit him. He stated that he did not wade in water before and
after the injury. Progressive swelling, redness, and pain over
his right foot developed in the subsequent days. His medical
histories were significant for diabetic mellitus, ureteral
stone, and hepatitis B carrier. At emergency room, he pre-
sented as conscious with toxic appearance and marked
prostration. His blood pressure was 146/94 mmHg, body
temperature was 38.1C, the respiratory rate was
20 breaths/min, and the heart rate was 114 beats/min.
Significant laboratory investigations revealed the following:
total white blood cell count, 38,500/mL with a left shift;
hemoglobin, 15.6 g/dL; platelet count, 245 103/mL; C-
reactive protein, 27.51 mg/dL (nephelometry; reference
range, <0.5 mg/dL); blood glucose, 787 mg/dL (reference
range, 70e115 mg/dL); serum creatinine, 1.46 mg/dL
(reference range, 0.7e1.2 mg/dL); lactate dehydrogenase,
235 IU/L (reference range, 133e225 IU/L); sodium,
124 mmol/L (reference range, 136e145 mmol/L); and
normal serum lactate and osmolality. A chest radiograph and
abdominal ultrasound revealed no significant abnormality.
On admission, the patient was febrile, with a body
temperature of 39C. His vital signs included a heart rate of
120 beats/min, a respiratory rate of 24 breaths/min, and
a blood pressure of 110/70 mmHg. The lesion around the
fish bite location healed well. Erythematous change with
local heat and profound tenderness, but no palpable
crepitance, and two vesicles on the right foot were found
(Fig. 1). Treatment was initiated with parenteral amoxi-
cillin/clavulanate plus gentamicin and doxycycline. On Day
2, fever persisted, and pain over his right foot exacerbated.
The follow-up C-reactive protein content was 39.9 mg/dL.
A random cortisol level was 3.31 mL, which was suggestive
of sepsis-related adrenal insufficiency. The value of D-dimer
was 922.44 ng/mL (reference range, <500 ng/mL); fibrin-
ogen was 606.1 mg/dL (reference range, 200e400 mg/dL);
and glycated hemoglobin (HbA1C) was 10.5% (referenceFigure 1. Erythematous change with two vesicles over right
foot.range, 4e6%). Amoxicillin/clavulanate was replaced by
ceftriaxone because of the positive report of Gram-nega-
tive bacilli in blood cultures. Needle aspiration was per-
formed from the bullas. About 1 mL of clear yellowish fluid
was drained out for studies. The Gram stain gave a negative
result. Chromobacterium violaceum was subsequently iso-
lated from the two sets of blood cultures. Identification was
confirmed by VITEK 2 System (bioMe´rieux) and API-20 NE
substrate-utilization test panel kit, Phoenix 100 System
(Beckson Diagnostic Instrument System). This bacterium is
beta-hemolytic and has positive catalase and oxidase
reactions. They were round and slightly raised with light
blue color, not purple, on blood agar plate (Fig. 2). The
colonies were not pigmented even after a 10-day period of
incubation. Antibiotic susceptibility tests revealed suscep-
tibility to ciprofloxacin, piperacillinetazobactam, levo-
floxacin, meropenem, aztreonam, ceftazidime, and
cefepime; intermediate susceptibility to gentamicin and
amikacin; and resistance to ampicillinesulbactam. In this
regard, the antimicrobial therapy was tailored to paren-
teral ciprofloxacin plus doxycycline. In addition, predniso-
lone (1 mg/kg everyday) for his relative adrenal
insufficiency was initiated on Day 3. Repeated blood culture
obtained 1 week after hospitalization yielded no microor-
ganism. The studies for leptospirosis and rickettsial infec-
tion were negative. He was discharged without sequelae
after treatment for 18 days. Therapeutic regimen with oral
ciprofloxacin 500 mg every 12 hours was maintained for 2
months in outpatient follow-up. There was no evidence of
recurrence after 3 months of evaluation.
Discussion
This case illustrates the importance of early appropriate
antimicrobial therapy to patient with C violaceum infectionFigure 2. The colonies were revealed to be round and
slightly raised with light blue in color, not purple, on blood agar
plate. They were not pigmented even after a 10-day period of
incubation.
Chromobacterium violaceum 403after fish bite with subsequent local infection in progres-
sion. It is impossible to differentiate between the infections
caused by C violaceum and other possible microorganisms,
including Staphylococcus spp., Streptococcus spp., Aero-
monas spp., Vibrio spp., Leptospira spp., and Burkholderia
pseudomallei, by patient’s initial presentation. Therefore,
the initial choice of antimicrobial therapy for such infection
should be broad enough to cover all of the possible micro-
organisms. Otherwise, the patient’s outcome will not be
satisfied. To date, only six cases with C violaceum infection
have been reported in Taiwan. Clinical features of these
patients and this reported case are listed in Table 1.4e8 In
view of the data, the case fatality rate was 65% (four of
seven), consistent with the report in the literature.1 Clinical
spectrum of C violaceum infection has a wide range,
including septicemia; cellulitis; lymphadenitis; pneumonia;
visceral abscesses involving the liver, spleen, brain, and
lung; urinary tract infection; gastroenteritis; intra-abdom-
inal abscess; conjunctivitis; nasopharyngeal abscess; septic
spondylitis; osteomyelitis; brain abscess; and meningi-
tis.1e3,9 This patient represented a rapidly progressive
cellulitis with sepsis. As shown in Table 1, six patients (85%)
had the problem of broken skin lesion and subsequently
progressed to cellulitis, consistent with literature review
results.1e3,8 Nevertheless, it is still possible to get this
infection from oral route or after near drowning.10
Furthermore, multiple abscesses could be the patient’s
initial manifestation.11
Although C violaceum is a normal habitant and is ubiq-
uitous in soil and water, the infected cases were few and
sporadic in the world.1e3 It may indicate the low infectivity
of C violaceum. However, Miller et al.12 had conducted
a study in 1988 comparing the virulent and avirulent strains
ofCviolaceum, inwhich virulent stain had elevated levels of
superoxide dismutase and catalase that may protect this
microorganism fromphagocytic attack in humans. Thus, it is
possible thatwhether patients developed this infectionmay
depend on the strain of C violaceum they contracted.
However, its excessive virulence usually causes life-
threatening sepsis once contracted.1e3 In this study, all of
the patients were bacteremic with obvious leukocytosis in
their initial presentations, consistent with the virulent
characteristic of this bacterium. Therewere pigmented and
nonpigmented colonies, with pigmented strains predom-
inating.1e3 Violacein, an antioxidant, from the pigmented
strain has a purple pigment giving it its typical color. Inter-
estingly, violacein has been considered to be a natural
antibiotic, and the biosynthesis, biological activities, and
the diverse effects of this pigment have been well studied.
As we know, aztreonam, a monocyclic beta-lactam antibi-
otic (a monobactam), is originally isolated from C viola-
ceum.13 In addition, this bacterium produces many
antibiotics used clinically and industrially.14 The colonies
cultured from this reported casewere nonpigmented,which
had not been reported in Taiwan previously. The non-
pigmented strain of C violaceum seems to be as virulent as
the pigmented strain.3
Whether innate immunologic dysfunction plays an
important role in C violaceum infection or not is still
controversial.1,3 Although chronic granulomatous disease
had been considered the risk factor since the report from
Macher et al. in 1982,15 most of the cases reported in theliterature were healthy. Of the cases in Taiwan, only this
reported case was immunocompromised. Probably, the
uncontrolled diabetes predisposed him to this infection
during the accident. There were only three patients (42.9%)
with the obvious history of exposure to water or soil, which
was inconsistent with literature. Accordingly, exposure to
water or soil or no exposure is not the crucial point in
consideration of C violaceum infection. However, with the
increasing outdoor activity, people may be at a greater risk
of C violaceum infection. Isolation of C violaceum by
culture from a clinical specimen (blood, abscess fluid, or
skin exudates) is the gold standard of diagnosis. There is no
diagnostic serologic test.
Optimal antimicrobial treatment and duration of C vio-
laceum infection are unknown. It is usually susceptible to
fluoroquinolones, chloramphenicol, tetracycline, trime-
thoprimesulfamethoxazole, imipenem, and gentamicin.1e3
According to the literature review, C violaceum is
frequently intrinsically resistant to penicillins and cepha-
losporins.16e18 Increased b-lactamase activity in C viola-
ceum has been reported in a study by Farrar et al. in 1976.19
In 1988, Aldridge et al.17 had conducted a study for the
comparison of the in vitro activities of ciprofloxacin and
other antimicrobial agents against clinical strains of C vio-
laceum, in which ciprofloxacin was found to be the most
active drug. In this study, the resistance rates of drugs to
various cephalosporins are shown as follows: cephalothin
(100%), cefamandole (100%), cefoxitin (36%), ceftizoxime
(64%), ceftriaxone (36%), and cefotaxime (45%). This result
indicates that the group of cephalosporins did not exhibit
a reliable susceptibility test to C violaceum, therefore, is
not the drug of choice for this infection. On the other hand,
cefazolin, oxacillin, amoxicillin/clavulanate, or ampicillin/
sulbactam, which used to be the first-line antibiotics for
common skin and soft tissue infections, are ineffective to
unusual pathogens, including Vibrio spp., Aeromonas spp.,
Leptospira spp., Burkholderia pseudomallei, and also C.
violaceum, which are endemic in Taiwan. Initial antimi-
crobial therapy with this first-line antibiotic alone for the
relevant infection is, therefore, not optimal. In this
reported patient, the initial antimicrobial coverage con-
sisted of parenteral amoxicillin/clavulanate and genta-
micin, and oral doxycycline. He seemed to respond very
well to it. Thus, this combination therapy could be an
initial option in treating patients with skin and soft tissue
infection caused by relevant pathogens in Taiwan. Subse-
quently, definite therapy, of course, should be tailored
promptly to drug susceptibility test. To give targeted
therapy for C violaceum infection, a fluoroquinolone in
combination with one of the aminoglycosides represents
the best treatment regimen according to in vitro data and
clinical experience in literature.9,17 However, it is worth
noting that several patients had experienced relapse or
recurrence even after completion of therapy with clinical
cure for C violaceum infection.18,20,21 The pathogenesis for
the frequent relapse or recurrence in patients with C vio-
laceum infection is still unknown. It is possible that occult
microabscess or hidden septic focus may persist in the
patient’s internal organs despite adequate treatment.
Therefore, treatment with parenteral antimicrobial agent
was recommended for 2e4 weeks and was to be maintained
with oral agents (e.g. trimethoprimesulfamethoxazole,
Table 1 Clinical features of seven cases with Chromobacterium violaceum infection in Taiwan
Case Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Present case
Year 1968 1998 1998 2002 2003 2005 2009
Age (years)/sex 2/F 44/M 73/F 5/M 20/M 80/F 64/M
Clinical presentation Cellulitis Cellulitis Cellullitis
Septic
spondylitis
Cellulitis
Conjunctivitis
Nasopharyngeal abscess
Intra-abdominal
abscess
Cellulitis Cellulitis
Comorbidity No Gall bladder
stones after
laparoscopic
cholecystectomy
No No No No Diabetes
Adrenal insufficiency
Exposure to
contaminated water/soil
Yes No No No No Yes Yes
Blood culture þ þ þ þ þ þ þ
Antibiotic use (initial drug) Chlorophenicol
þ gentamicin
Piperacillin
(oxacillin)
Ciprofloxacin
þ piperacillin
(cefazolin)
Penicillinþ oxacillin
þ netilmicin
(cefazolin)
Flomoxef Levofloxacin
(cefotaxime)
Ciprofloxacin
(augmentinþ gentamicin)
Doxymycin
Initial white blood
cell count (mm3)
20,800 19,500 11,000 21,750 21,000 16,860 38,500
Outcome Died Died Survived Died Died Survived Survived
Reference Wu et al.4 Chou et al.5 Chou et al.5 Shao et al.6 Chen et al.7 Change et al.8
FZ female; MZmale; þZ positive.
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Chromobacterium violaceum 405doxycycline, or fluoroquinolones) for an extended period
(2e3 months) to prevent relapse in patients with C viola-
ceum infection.9,17,22
In conclusion, patients with a distinct history of trau-
matic injury by creatures in river with subsequent local
infection in progression should alert the clinician to list C
violaceum as the probable pathogen. A combination of
prompt diagnosis, optimal antimicrobial therapy, and
adequate therapeutic duration for C violaceum infection is
the key for successful therapy.
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